-
Chest pain presentations to the emergency department (ED) are common and very costly to the health care system. Although the event rates are low in patients with a low clinical risk profile, the price of a missed diagnosis is high.
-
After results of the pivotal NINDS intravenous thrombolysis (IV rtPA) trial were published in 1995, there has been a gradual extension of the time window from 3 hours to 4.5 hours, based on additional trials (ECASS II and III).
-
-
Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
-
The recently published IST-3 trial has stimulated great interest in the expanded use of intravenous thrombolysis (IV rtPA). Wardlaw and colleagues assessed all of the evidence from published randomized trials for IV rtPA in acute ischemic stroke using a meta-analysis.
-
Patients with diabetes mellitus (DM) are at increased risk of developing acute coronary syndromes (ACS). Furthermore, after hospitalization with ACS, patients with DM are at increased risk of suffering repeat hospitalization for ACS.
-
Good news: More women are choosing long-acting reversible contraceptives (LARC methods) such as the intrauterine device (IUD) and the contraceptive implant.
-
The Centers for Disease Control and Prevention (CDC) has issued new interim guidance for use of pre-exposure prophylaxis (PrEP) for in heterosexual men and women at high risk for HIV.
-
Findings from a just-published study of young women ages 13-16 in Cincinnati are the first to document herd protection after introduction of the human papillomavirus (HPV) vaccine.
-
The North American Menopause Society, the American Society for Reproductive Medicine, and The Endocrine Society have issued a joint statement concluding that hormone therapy (HT) is still an acceptable treatment for menopausal symptoms.
